NASDAQ:OPK • US68375N1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OPKO HEALTH INC (OPK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-20 | JP Morgan | Initiate | Neutral |
| 2025-10-31 | Jefferies | Downgrade | Buy -> Hold |
| 2025-10-30 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-05-01 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-04-25 | JP Morgan | Initiate | Neutral |
| 2025-04-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-28 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-17 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-07-18 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-01 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-04-01 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-02-28 | Barrington Research | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 863.495M -14.01% | 713.142M -17.41% | 606.879M -14.90% | 559.31M -7.84% | 585.95M 4.76% | 631.18M 7.72% | 654.73M 3.73% | 695.23M 6.19% | 695.18M -0.01% | 723.67M 4.10% | 753.97M 4.19% | |
| EBITDA YoY % growth | -51.724M 62.02% | -175.382M -239.07% | -127.358M 27.38% | -82.063M 35.57% | -13.08M 84.06% | 52.554M 501.80% | 95.849M 82.38% | 146.45M 52.79% | 177.26M 21.04% | 198.97M 12.25% | 211.09M 6.09% | |
| EBIT YoY % growth | -157.021M 35.88% | -273.558M -74.22% | -218.985M 19.95% | -171.15M 21.84% | -100.091M 41.52% | -29.391M 70.64% | 13.736M 146.74% | 60.802M 342.65% | 87.87M 44.52% | 105.95M 20.58% | 114.13M 7.72% | |
| Operating Margin | -18.18% | -38.36% | -36.08% | -30.60% | -17.08% | -4.66% | 2.10% | 8.75% | 12.64% | 14.64% | 15.14% | |
| EPS YoY % growth | -0.25 44.07% | -0.21 14.66% | -0.30 -42.86% | -0.27 8.62% | -0.24 12.81% | -0.08 68.31% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 32.19% | -0.07 64.31% | -0.06 -295.27% | -0.05 -36.35% |
| Revenue Q2Q % growth | 133.98M -10.62% | 139.71M -10.90% | 146.25M -3.59% | 153.52M 3.38% |
| EBITDA Q2Q % growth | -12.322M 71.79% | -13.383M 0.63% | -1.717M -110.91% | -606K -101.14% |
| EBIT Q2Q % growth | -45.291M 32.57% | -44.757M 25.38% | -38.076M 28.86% | -34.585M 9.74% |
All data in USD
11 analysts have analysed OPK and the average price target is 3.63 USD. This implies a price increase of 201.2% is expected in the next year compared to the current price of 1.205.
OPKO HEALTH INC (OPK) will report earnings on 2026-04-28.
The consensus EPS estimate for the next earnings of OPKO HEALTH INC (OPK) is -0.07 USD and the consensus revenue estimate is 133.98M USD.
The expected long term growth rate for OPKO HEALTH INC (OPK) is 1.47%.